BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38177659)

  • 21. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
    Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
    Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of
    Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral
    Yamamura K; Izumi D; Kandimalla R; Sonohara F; Baba Y; Yoshida N; Kodera Y; Baba H; Goel A
    Clin Cancer Res; 2019 Oct; 25(20):6170-6179. PubMed ID: 31358543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers.
    Ma F; Li Y; Xiang C; Wang B; Lv J; Wei J; Qin Z; Pu Y; Li K; Teng H; Tan S; Feng J; Shang Z; Wang Y; Tian S; Du C; Han Y; Ding C
    J Hematol Oncol; 2024 Mar; 17(1):11. PubMed ID: 38491392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
    Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
    Front Immunol; 2022; 13():970534. PubMed ID: 36275724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative RECIST derived from multiparametric MRI in evaluating response of esophageal squamous cell carcinoma to neoadjuvant therapy.
    Qu J; Zhang Y; Lu S; Xing W; Zheng Y; Sun H; Gao Q; Xia Q; Wang Z; Zhang H; Wang S; Qin J; Kamel IR; Li H
    Eur Radiol; 2022 Oct; 32(10):7295-7306. PubMed ID: 36048205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
    Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
    Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
    Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
    Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of
    Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
    J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of primary lung cancer and benign pulmonary nodules: a comparison of the breath test and 18F-FDG PET-CT.
    Ding X; Lin G; Wang P; Chen H; Li N; Yang Z; Qiu M
    Front Oncol; 2023; 13():1204435. PubMed ID: 37333820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
    Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
    Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
    Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
    JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer.
    Liu J; Chen H; Li Y; Fang Y; Guo Y; Li S; Xu J; Jia Z; Zou J; Liu G; Xu H; Wang T; Wang D; Jiang Y; Wang Y; Tang X; Qiao G; Zhou Y; Bai L; Zhou R; Lu C; Wen H; Li J; Huang Y; Zhang S; Feng Y; Chen H; Xu S; Zhang B; Liu Z; Wang X
    J Hematol Oncol; 2023 Jun; 16(1):63. PubMed ID: 37328852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.
    Wen J; Luo K; Liu H; Liu S; Lin G; Hu Y; Zhang X; Wang G; Chen Y; Chen Z; Li Y; Lin T; Xie X; Liu M; Wang H; Yang H; Fu J
    Ann Surg; 2016 May; 263(5):942-8. PubMed ID: 26445467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma.
    Matsumoto S; Wakatsuki K; Nakade H; Kunishige T; Miyao S; Tsujimoto A; Tatsumi T; Sho M
    Langenbecks Arch Surg; 2022 May; 407(3):965-974. PubMed ID: 34989856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
    Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
    Front Immunol; 2021; 12():772450. PubMed ID: 34938292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.